From: In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line
AATSC8c
MATS8c
SpMAD_Dzs
BCUTc-1 l
1
0.989573
0.194418
0.168297
BCUTc-1l
− 0.1423
-0.12496
0.000392